Details
|
BioCryst Pharmaceutical Incorporation focuses on development, optimization, and design of small-molecule medications for treatment viral infections, cancer, autoimmune and cardiovascular diseases. BioCryst engages in building selective, potent enzymes inhibitors associated with targeted disorders. The company is integrating computer modeling, medicinal chemistry, crystallography, and biology disciplines to use structure-based medicine design to develop and discover small molecules pharmaceuticals. BioCryst Pharmaceuticals' major drug candidate is a transition-state analog inhibitor, called Fodosine which is in a phase 1 study for patients with oral cutaneous T-cell lymphoma and in phase 2a with T-cell leukemia. BioCryst's pipeline drugs include Tissue Factor/Factor VIIa inhibitors-for treatment of complications after cardiovascular procedures and acute coronary syndrome; BCX-4208(PNP inhibitor) -intended for treatment of T-cell mediated autoimmune disorders such as psoriasis; and Hepatitis C Polymerase inhibitor indicated for viral infections treatment. BioCryst Pharmaceutical inc., is collaborating with Sunol Molecular corporation to supply and conduct research of proteins targets for medicine design for its cardiovascular programs. The company was discovered by William Spencer III, John Montgomery, and Charles Bugg in 1986. BioCryst is based In Birmingham, state Alabama. Website: www.biocryst.com Tel #: 205-444-4600. The company is publicly traded on Nasdaq under BCRX symbol.
|
